GNR-055
Phase 3Biologic
GNR-055 is one of 8 biologic programs targeting Mucopolysaccharidosis. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Mucopolysaccharidosis
#DrugCompanyPhaseTrials
1Rituxan
RocheApproved
Trexall
Jazz PharmaceuticalsApproved
Neoral
NovartisApproved
Imuran
LLegacy Health System
Approved
GNR-055
AAO GENERIUM
Phase 3
JR-446
JJCR Pharmaceuticals Co., Ltd.
Phase 2
Enzyme Replacement Agent
FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Preclinical
Laronidase ERT
MMasonic Cancer Center, University of Minnesota
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cohort Study1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GNR-055. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- AAO GENERIUM